Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.53 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 4/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 4/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.47 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968619 | 0.90 | RIPK1 (0.54) | IGF1RPLCG1AXLNEK1MAP3K11 | |
| SCHEMBL11968615 | 0.90 | MAP3K11 (0.51) | PLCG1AXLMAP3K11ABL1NTRK1 | |
| SCHEMBL11968623 | 0.89 | SGK1 (0.56) | AXLNEK1MAP3K11ABL1NTRK1 | |
| SCHEMBL11968643 | 0.89 | NTRK1 (0.60) | IGF1RPLCG1AXLNEK1MAP3K11 | |
| SCHEMBL11968613 | 0.89 | NEK1 (0.58) | PLCG1NEK1MAP3K11ABL1NTRK1 | |
| SCHEMBL11968616 | 0.88 | MAP3K11 (0.49) | PLCG1AXLNEK1MAP3K11ABL1 | |
| SCHEMBL11968632 | 0.86 | CAMKK2 (0.59) | IGF1RPLCG1AXLNEK1ABL1 | |
| SCHEMBL11968620 | 0.86 | RIPK1 (0.55) | IGF1RAXLNEK1RIPK1 | |
| SCHEMBL11968642 | 0.86 | NEK1 (0.61) | PLCG1AXLNEK1ABL1NTRK1 | |
| SCHEMBL11968641 | 0.86 | ABL1 (0.54) | PLCG1AXLNEK1MAP3K11ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | IGF1R 828/4885PLCG1 775/4885AXL 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.